contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


orexo-publishes-the-annual-and-sustainability-report-for-2024

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Orexo is a Swedish pharmaceutical company that develops improved medicines based on proprietary formulation technologies and with a focus on meeting major medical needs. In the US market, Orexo commercializes treatments for patients suffering from opioid addiction. Products targeting other therapeutic areas are developed and commercialized worldwide through partners.

Orexo

Uppsala, Sweden - March 28, 2025 – Orexo’s Annual and Sustainability Report for 2024 has been published. It is attached as a PDF to this press release and can be downloaded at https://orexo....

<div class="mfn-body"><p><strong>Uppsala, Sweden - March 28, 2025 –</strong> Orexo’s Annual and Sustainability Report for 2024 has been published. It is attached as a PDF to this press release and can be downloaded at <a rel="noopener" href="https://orexo.com/investors/">https://orexo.com/investors/</a>.</p><p><strong>Nikolaj Sørensen, President and CEO, reflects on 2024:</strong><em> Orexo has made significant strides in overcoming challenges and seizing new opportunities. We achieved EBITDA profitability and resolved key legal and financial uncertainties. Continued stabilization in Zubsolv® demand and the advancement of OX640,[1] along with the ongoing development of the AmorphOX® platform, mean we’re positioned well for a promising 2025. With a dedicated team, we are set to embrace new opportunities to deliver our mission to address critical patient needs and drive shareholder value.”</em></p><p><strong>The Annual and Sustainability Report includes:</strong></p><ul><li><strong>Orexo Overview:</strong> Insights covering areas such as operations, markets and investment themes, as well as the CEO's comments and the company’s strategic direction.</li><li><strong>Reports:</strong> The Board of Directors Report (incl. the Sustainability Report), the Corporate Governance Report, and Financial Reports and Notes.</li></ul><p>The Swedish version is also available on the company´s website in European Single Electronic Format (ESEF).</p><p>For more information about Orexo, visit <a rel="noopener" href="http://www.orexo.com/">www.orexo.com</a>, and stay updated by following us on X and LinkedIn.</p><table><tbody><tr><td rowspan="1" colspan="1"><strong>For further information contact:</strong><strong><br></strong><strong><br></strong>Lena Wange, IR &amp; Communications Director</td></tr><tr><td rowspan="1" colspan="1">Tel: +46 18&nbsp;780 88 00</td></tr><tr><td rowspan="1" colspan="1">e-mail: <a rel="noopener" href="mailto:ir@orexo.com">ir@orexo.com</a></td></tr></tbody></table><p><strong>About Orexo</strong><br>Orexo is a Swedish pharmaceutical company with 30 years of experience developing improved pharmaceuticals based on proprietary drug delivery technologies that meet large medical needs. On the US market, Orexo provides innovative treatment solutions for patients suffering from opioid use disorder. Products targeting other therapeutic areas are developed and commercialized worldwide with leading partners. Total net sales in 2024 amounted to SEK 590 million, and the number of employees to 110. Orexo is listed on Nasdaq Stockholm’s main list and is available as ADRs on OTCQX market (ORXOY) in the US.</p><p>[1] Rescue medication for allergic reactions, incl. anaphylaxis, with powder-based epinephrine.</p></div><div class="mfn-footer mfn-regulatory mfn-regulatory-vpml"><p><em>This information is information that Orexo AB is obliged to make public pursuant to the Securities Markets Act. The information was submitted for publication, through the agency of the contact persons set out above, at 2025-03-28 08:00 CET.</em></p></div><div class="mfn-footer mfn-attachment mfn-attachment-image"><p><strong class="mfn-heading-1">Image Attachments</strong><br><a rel="noopener" href="https://storage.mfn.se/3eaa11ed-1625-482b-8169-054ccfe6eee7/00-omslag-framsidaxeng-v15-26375.jpeg">00 Omslag FramsidaXENG V15 26375</a></p></div><div class="mfn-footer mfn-attachment mfn-attachment-general"><p><strong class="mfn-heading-1">Attachments</strong><br><a rel="noopener" href="https://storage.mfn.se/8179ed3b-7d02-431b-954c-944f429471fd/orexo-annual-and-sustainability-report-2024.pdf" class="mfn-primary">Orexo Annual And Sustainability Report 2024</a><br><a rel="noopener" href="https://storage.mfn.se/df3619bd-c8ce-4b9b-9364-5f469cdc5005/orexoab-2024-12-31-0-sv.zip">orexoab-2024-12-31-0-sv</a></p></div>